2004
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis. Journal Of Clinical Oncology 2004, 22: 854-863. PMID: 14990641, DOI: 10.1200/jco.2004.04.158.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBreast NeoplasmsCohort StudiesCost SavingsCost-Benefit AnalysisDecision Support TechniquesDose-Response Relationship, DrugDrug Administration ScheduleDrug CostsFemaleGenes, erbB-2Genetic TestingHealth Care CostsHumansMarkov ChainsNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingQuality of LifeSurvival RateTrastuzumabTreatment OutcomeConceptsIncremental cost-effectiveness ratioMetastatic breast cancer patientsBreast cancer patientsTrastuzumab therapyCancer patientsFavourable incremental cost-effectiveness ratioTest characteristicsMetastatic breast cancerCost-effectiveness ratioEffectiveness of treatmentPositive test resultsNegative test resultsPositive resultsCost-effectiveness analysisTreatment strategiesBreast cancerHypothetical cohortTreatment candidatesHercepTest resultsPatientsClinical practiceFISH confirmationProtein overexpressionLifetime costsHercepTest
2000
Testing for Hereditary Breast and Ovarian Cancer in the Southeastern United States
Miron A, Schildkraut J, Rimer B, Winer E, Skinner C, Futreal P, Culler D, Calingaert B, Clark S, Marcom P, Iglehart J. Testing for Hereditary Breast and Ovarian Cancer in the Southeastern United States. Annals Of Surgery 2000, 231: 624-634. PMID: 10767783, PMCID: PMC1421049, DOI: 10.1097/00000658-200005000-00002.Peer-Reviewed Original ResearchConceptsProphylactic surgeryPreventive surgeryOvarian cancerFree genetic testingProspective clinical trialsBreast cancer patientsHereditary breast cancerPositive test resultsUncertain clinical significanceMore heterogeneous populationsBaseline characteristicsCancer patientsBaseline questionnaireClinical trialsTime of entryBreast cancerClinical significanceHeterogeneous syndromeSurgeryHereditary breastNumber of womenDeleterious gene mutationsBRCA2 genesGenetic testingSpecial populations
1997
Genetic Testing for Susceptibility to Breast Cancer: Findings from Women's Focus Groups
Tessaro I, Borstelmann N, Regan K, Rimer B, Winer E. Genetic Testing for Susceptibility to Breast Cancer: Findings from Women's Focus Groups. Journal Of Women's Health 1997, 6: 317-327. PMID: 9201666, DOI: 10.1089/jwh.1997.6.317.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingLoss of insuranceSupport needsPositive test resultsWomen's focus groupsFocus groupsUnaffected womenLifestyle changesMore public educationWomen's knowledgeMedical treatmentBRCA1 testingBRCA1 mutationsCancerWomenLifestyle choicesEffect of testingBalanced informationWomen's decisionsPhysiciansFamily membersFocus group discussionsSuch testingWomen's concerns